Gene Therapy Strategies and Applications for Cancer

Xinyan Lou

doi:10.54097/mrnqz038

Authors

Xinyan Lou

DOI:

https://doi.org/10.54097/mrnqz038

Keywords:

Gene Therapy, Tumor Treatment, Gene Expression

Abstract

With the advancement of medical technology, people have made some new progress and breakthroughs in the treatment of tumors and cancers, especially in the aspect of genetic intervention, This paper introduced the process of different gene therapy strategies for treating diseases and the application of various gene therapy strategies in tumor treatment research, which can provide researchers with a basic knowledge framework for

Downloads

Download data is not yet available.

References

[1] Yang, L., Huang, C., Wang, M. (2020) Advances in Gene Therapy for Cancer. J. Sci. Commun., 3: 001.

[2] Liu, J. (2006) The Strategy of Cancer Gene Therapy. J. Sci. Commun., 3: 179–186.

[3] Navarro, S.A., Carrillo, E., Grinan-Lison, C., et al. (2016) Cancer suicide gene therapy: a patent review. Expert Opin. Ther. Pat., 26: 1095–1104.

[4] Shao, D., Li, J., Xiao, X., et al. (2014) Real-time visualizing and tracing of HSV-TK/GCV suicide gene therapy by near-infrared fluorescent quantum dots. ACS Appl. Mater. Interfaces, 6: 11082–11090.

[5] Lee, M., Kim, Y.S., Lee, K., et al. (2019) Novel Semi-Replicative Retroviral Vector Mediated Double Suicide Gene Transfer Enhances Antitumor Effects in Patient-Derived Glioblastoma Models. Cancers, 11: E1090.

[6] Gujrati, M., Lu, Z.R. (2014) Targeted Systemic Delivery of Therapeutic siRNA. Gene Ther. Cancer, 3: 51–59.

[7] Sato, Y., Murase, K., Kato, J., et al. (2008) Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat. Biotechnol., 26: 431–442.

[8] Pang, W., Zhai, M., Wang, Y., et al. (2019) Long noncoding RNA SNHG16 silencing inhibits the aggressiveness of gastric cancer via upregulation of microRNA-628-3p and consequent decrease of NRP1. Cancer Manag. Res., 11: 7263–7277.

[9] Singh, A., Trivedi, P., Jain, N.K. (2018) Advances in siRNA delivery in cancer therapy. Artif. Cells Nanomed. Biotechnol., 46: 274–283.

[10] Davis, M.E. (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm., 6: 659–668.

[11] Tabernero, J., Shapiro, G.I., LoRusso, P.M., et al. (2013) First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov., 3: 406–417.

[12] Fung, H., Gersson, S. (2014) Viral insertion site detection and analysis in cancer gene therapy. Gene Ther. Cancer, 3: 35–46.

[13] Deng, Y., Zhao, Y., Cheng, F., et al. (2014) The latest research progress of tumor suppressor gene NDRG2. J. Mod. Oncol., 4: 962–965.

[14] Lin, J., Chen, H., Wang, D., et al. (2019) Nuclear-targeted p53 and DOX co-delivery of chitosan derivatives for cancer therapy in vitro and in vivo. Elsevier, 183: 114–137.

[15] Lievre, A., Landi, B., Cote, J.F., et al. (2005) Absence of mutation in the putative tumor-suppressor gene KLF6 in colorectal cancers. Oncogene, 24: 7253–7256.

[16] Guo, C., Ding, J., Yao, L., et al. (2005) Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1. Int. J. Cancer, 116: 155–160.

[17] Reardon, D.A., Wucherpfennig, K.W., Freeman, G., et al. (2013) An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev. Vaccines, 12: 597–615.

[18] Wolff, J.A., Budker, V. (2005) The mechanism of naked DNA uptake and expression. Adv. Genet., 54: 3–20.

[19] Lopes, A., Vandermeulen, G., Préat, V. (2019) Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J. Exp. Clin. Cancer Res., 38: 146.

[20] Lambertini, M., Pondé, N.F., Solinas, C., et al. (2017) Adjuvant trastuzumab: a 10-year overview of its benefit. Expert Rev. Anticancer Ther., 17: 61–74.

[21] Salles, G., Barrett, M., Foà, R., et al. (2017) Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv. Ther., 24: 2232–2273.

[22] Park, T., Choi, C.J., Choi, Y., et al. (2016) Cost-effectiveness of cetuximab for colorectal cancer. Expert Rev. Pharmacoecon. Outcomes Res., 16: 667–677.

[23] Diaz, R.J., Ali, S., Qadir, M.G., et al. (2017) The role of bevacizumab in the treatment of glioblastoma. J. Neurooncol., 133: 455–467.

[24] Yaghoubi, S., Karimi, M.H., Lotfinia, M., et al. (2019) Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy. J. Cell. Physiol., 234: 1–34.

[25] Hinrichs, C.S., Stevanović, S., Draper, L., et al. (2014) HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. Clin. Oncol., 32: 233–245.

[26] Guzik, K., Zak, K.M., Grudnik, P., et al. (2017) Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. J. Med. Chem., 60: 5857–5867.

[27] Ahmed, S.R., Petersen, E., Patel, R. (2019) Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Expert Rev. Clin. Pharmacol., 12: 1–5.

[28] Lin, X., Khalid, S., Qureshi, M.Z., et al. (2016) VEGF mediated signaling in oral cancer. Cell. Mol. Biol., 62: 64–68.

[29] Sopo, M., Anttila, M., Sallinen, H., et al. (2012) Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma. Cancer, 131: 2394–2401.

[30] Tuppurainen, L., Sallinen, H., Kokki, E., et al. (2013) Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer. Hum. Gene Ther. Clin. Dev., 24: 29–37.

[31] Shi, X., Cheng, Y. (2009) Gland virus mediated P53 gene to treat bladder cancer. J. Cancer Res. Ther., 1: 180–184.

[32] Li, W. (2006) Modifying autologous lymphocyte genes are expected to treat skin cancer. Foreign Med. Sci., 10: 27–28.